title: Human leukocyte antigens class II genes are associated with cancer development in the autoimmune rheumatic diseases.
abstract: OBJECTIVE
  To determine the association between HLA class II alleles and the probability of developing cancer in patients with autoimmune rheumatic diseases. MATERIAL AND METHODS; A matched case control study was conducted in which patients with autoimmune rheumatic disease who later developed malignancy (solid or lymphoproliferative) were compared with matched controls suffering from the same auto-immune rheumatic disease and with similar disease duration. The rheumatic diseases included rheumatoid arthritis, systemic lupus erythematosus, primary Sjögren syndrome, dermatomyositis-polymyositis, and systemic sclerosis. HLA-DR typing was performed by sequence-specific primers after DNA amplification by PCR (PCR-SSP). Statistical analysis was conducted by conditional logistic regression.
  
  
  RESULTS
  HLA-DRBI*02 and DRBI*03 were found to be significantly associated with the probability for developing cancer (OR = 5.2 and 4.9, respectively), independent of family history of rheumatoid arthritis and cancer, recurrent sore throat, alopecia, and clinical activity of rheumatoid arthritis.
  
  
  CONCLUSIONS
  The results suggest an association between HLA class II alleles with the probability of developing a malignant neoplasm in patients suffering from an autoimmune rheumatic disease.
authors: Departamento de Genètica, Institute Nacional de Rehabilitación, México, DF.
authors: Antonio
authors: A
authors: Miranda-Duarte
authors: Arnoldo
authors: A
authors: Kraus-Weisman
authors: Julio
authors: J
authors: Granados
authors: Antonio R
authors: AR
authors: Vill
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology*; D016022:Case-Control Studies; D015897:Comorbidity; D003937:Diagnosis, Differential; D004198:Disease Susceptibility; D005192:Family Health; D005260:Female; D005802:Genes, MHC Class II; D006684:HLA-DR Antigens / Q000032:analysis / Q000235:genetics*; D059811:HLA-DRB1 Chains; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology / Q000276:immunology*; D010257:Paraneoplastic Syndromes / Q000175:diagnosis; D010612:Pharyngitis / Q000453:epidemiology; D012008:Recurrence; D012216:Rheumatic Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology*; D013997:Time Factors
chemical_list: D018501:Antirheumatic Agents; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; C521115:HLA-DRB1*02 antigen; D007166:Immunosuppressive Agents